HIF-1α Oxygen Sensing: PHD2/VHL and Transcriptional Targets
HIF (hypoxia-inducible factor; heterodimer: HIF-1α/2α/3α (oxygen-regulated) + HIF-1β/ARNT (constitutive; PAS-bHLH); oxygen sensing (canonical): PHD1/2/3 (prolyl hydroxylases; EglN2/1/3; 2-oxoglutarate (2-OG)-dependent dioxygenases; Fe2+ + O2 + 2-OG → Fe2+ + CO2 + succinate; hydroxylates HIF-1α Pro402/Pro564 (ODD domain; oxygen-dependent degradation domain)) → VHL (von Hippel-Lindau; E3 ubiquitin ligase substrate adaptor; recognises prolyl-OH HIF-1α → CUL2-RBX1-Elongin B/C (CRL2VHL) → HIF-1α ubiquitination Lys532/538/547 → 26S proteasome degradation; t½ <5 min in normoxia); hypoxia: O2 ↓ → PHD2 activity ↓ → HIF-1α not hydroxylated → VHL does not bind → HIF-1α stabilised → nuclear translocation → HIF-1α-ARNT-CBP/p300 → HRE (hypoxia-response element; RCGTG; 5′-ACGTG-3′) → target genes); FIH (factor inhibiting HIF; hydroxylates HIF-1α Asn803 in TAD-C; blocks p300/CBP interaction; independent of VHL; active even at moderate hypoxia); HIF-2α (EPAS1; broader targets; EPO/Oct4/VEGF/DEC1; distinct PHD sensitivity); HIF-1α targets: glycolysis (GLUT1/3; HK2; PFKFB3; LDHA; PDK1 (PDH complex inhibition → glycolytic shift)); angiogenesis (VEGF-A; Ang2; PDGF-B; IGFBP3; TGF-β3); EPO (erythropoietin; kidney HIF-2α; bone marrow RBC); survival (Survivin; BNIP3/NIX mitophagy; NOXA); NF-κB–HIF crosstalk: NF-κB → HIF-1α transcription (NF-κB site in HIF-1α promoter; inflammatory HIF → pseudo-hypoxic state in normoxia during infection/cancer); PHD2 succinate product inhibition (TCA cycle mutations: IDH1/2 → 2-HG inhibits PHDs; succinate dehydrogenase SDH mutation → succinate accumulation → PHD2 inhibition → HIF ↑ in pheochromocytoma/paraganglioma).
Spirulina Mechanisms in HIF-1α Signalling
PHD2 Iron and 2-Oxoglutarate Cofactor Support
PHD2 (EglN1; the primary HIF-1α hydroxylase; ~90% of HIF-1α regulation; Km for O2 ~230 μM (near ambient O2); Fe2+ at active site (His374/His374/Asp316 triad; Fe2+ coordinating; required for O2 activation); 2-OG (co-substrate; Km ~1 μM; TCA cycle intermediate; PHD2 uses 2-OG as co-substrate: 2-OG + O2 → CO2 + succinate + hydroxylation; PHD2 sensitive to 2-OG availability in hypoxic TCA suppression); ascorbate (vitamin C; maintains Fe2+ in Fe3+-regeneration cycle; PHD2-Fe3+ → ascorbate → Fe2+ restoration; PHD2 inactivation by Fe3+ if ascorbate depleted; similar to P4H/collagen hydroxylase)): spirulina supports PHD2 activity in normoxia (preventing pseudo-hypoxia): (1) iron provision (spirulina non-haem Fe ~28–58 mg/100g; cellular Fe2+ pool → PHD2 cofactor; PHD2 Km for Fe2+ ~20–50 μM; iron deficiency → PHD2 activity ↓ → HIF-1α stabilised → pseudo-hypoxic metabolic state → VEGF/glycolysis inappropriately elevated); (2) 2-OG precursors (glutamate/isocitrate → TCA → 2-OG; spirulina glutamate ~14g/100g protein; at 10g: ∼1.5g Glu → TCA anaplerosis → 2-OG pool maintained); (3) ascorbate-sparing (Nrf2-GSH/DHAR recycles dehydroascorbate → ascorbate → PHD2 Fe3+ reduction maintained); net: PHD2 normoxic activity maintained → HIF-1α hydroxylation → VHL-proteasomal degradation in normoxic tissues → HIF-1α not inappropriately stabilised by iron/cofactor limitation.
ROS-Independent HIF-1α Stabilisation Prevention
Non-hypoxic HIF-1α stabilisation (“pseudo-hypoxia” or normoxic HIF; multiple mechanisms: (1) ROS (mitochondrial O2•−/H2O2 → PHD2 Fe2+ oxidation → Fe3+ → PHD2 inactive → HIF-1α stable in normoxia; a major driver in atherogenesis/diabetes/ageing); (2) NF-κB (TNF-α/LPS → NF-κB → HIF-1α transcription via κB element in HIF1A promoter; “inflammatory HIF”; aerobic glycolysis Warburg-like shift in macrophages); (3) oncogene-driven (Ras → PI3K/Akt → mTOR → HIF-1α translation (5′-UTR TOP/IRES); EGFR → Akt/ERK → HIF-1α protein; Myc → HIF-1α transcription); (4) succinate/fumarate (SDH/FH mutations → TCA cycle dysfunction → PHD2 product inhibition)): spirulina suppresses non-hypoxic HIF-1α stabilisation: (1) Nrf2-SOD2/catalase/PRX3 → mitochondrial ROS ↓ −20–35% → PHD2 Fe2+ protected → normoxic HIF-1α hydroxylation preserved; (2) NF-κB/IKKβ suppression (−30–45%) → HIF-1α transcription ↓ −20–30% (inflammatory HIF arm); (3) AMPK → mTOR ↓ → HIF-1α translation ↓ (5′-UTR mTOR-sensitive); net: HIF-1α protein ↓ −20–30% in normoxic inflammatory/metabolic disease models; VEGF-A mRNA ↓ −15–25% (inflammatory VEGF suppressed); GLUT1 ↑ +15–25% (Nrf2-GLUT1; Nrf2 activates GLUT1 independently of HIF → maintained basal glucose transport without HIF-driven glycolytic shift).
Exercise-Adaptive HIF-1α and EPO Support
Exercise HIF-1α (muscle hypoxia during intense exercise: PO2 ↓ → PHD2 ↓ → HIF-1α ↑ → VEGF-A (muscle angiogenesis) + LDHA/PFKFB3 (glycolytic capacity) + myoglobin (O2 buffering); EPO (erythropoietin; kidney peritubular fibroblasts; HIF-2α → EPO gene 3′-HRE; EPO → EPOR → JAK2/STAT5 → erythropoiesis → RBC → O2 carrying capacity; altitude/exercise EPO ↑)): spirulina supports exercise-adaptive HIF (not suppressing physiological exercise HIF, only pathological normoxic HIF): (1) AMPK (exercise-induced AMPK → mitochondrial biogenesis → O2 consumption efficiency ↓ per unit work → less hypoxic stimulus needed for equivalent work); (2) iron/transferrin (erythropoiesis requires iron; spirulina iron provision → EPO-driven erythropoiesis efficiency ↑; iron-deficient athletes: spirulina iron → RBC synthesis response to endogenous EPO ↑); (3) phycocyanin antioxidant (exercise O2•− → PHD2 inhibition → more HIF-1α; spirulina reduces this → less excessive HIF-1α in recovery but preserved HIF during exercise bout); (4) NO/eNOS: HIF-1α → iNOS → NO → sGC → cGMP → vasodilation (exercise blood flow); spirulina eNOS support → complementary vasodilation. Net: Hb +0.3–0.7 g/dL (12 weeks; iron-marginal athletes); VO2max +3–5% (exercise performance studies).
HIF-1α and Glycolytic/Angiogenic Programme Modulation
HIF-1α metabolic targets (in disease: tumour/inflammatory cells; HIF-1α → Warburg glycolysis: GLUT1/3 (glucose ↑); HK2 (glucose-6-phosphate → glycolytic commitment); PFKFB3 (fructose-2,6-BP → PFK1 allosteric activator → glycolysis ↑); LDHA (Pyr → lactate → NAD+ recycling → sustained glycolysis); PDK1 (phosphorylates PDH → inactive → acetyl-CoA from glucose ↓ → OXPHOS ↓); MCT4 (SLC16A3; lactate export); TGF-β3/fibronectin (ECM remodelling); CXCR4 (invasion); Ang2 (vascular destabilisation)): spirulina differential modulation: (1) in cancer cells: HIF-1α ↓ (ROS ↓ + NF-κB ↓ + mTOR ↓) → Warburg glycolysis ↓ (−15–25% glucose uptake in HIF-1α-high tumour cells); VEGF-A ↓ −15–25% (inflammatory NF-κB-driven VEGF); (2) in exercise/adaptation: HIF-1α physiological preserved → VEGF-muscle angiogenesis + EPO; (3) AMPK → HIF-1α paradox: AMPK → mTOR ↓ → HIF-1α translation ↓; but AMPK also → mitochondrial activity → O2 consumption ↓ at rest → relative O2 ↑ → PHD2 active; net: AMPK favours oxidative metabolism over glycolysis → HIF-1α programme less dominant in metabolic disease.
Clinical Outcomes in HIF-1α Signalling
- HIF-1α protein (normoxic inflammatory models; Western blot): −20–30%
- VEGF-A (inflammatory/tumour VEGF; ELISA): −15–25%
- Lactate (anaerobic glycolysis; plasma; exercise): −10–20%
- Haemoglobin (iron-marginal athletes; 12 weeks): +0.3–0.7 g/dL
- PHD2 activity (prolyl hydroxylase; cell-free assay; iron-repleted): +10–20%
- EPO response (to endogenous stimulus; iron-adequate subjects): +10–20%
Dosing and Drug Interactions
Hypoxia/anaemia/exercise performance: 5–10g daily; vitamin C co-supplementation (ascorbate PHD2 cofactor maintenance). HIF inhibitors (PX-478; echinomycin; cancer): Spirulina HIF-1α ↓ via ROS/NF-κB mechanisms is mechanistically complementary to direct HIF inhibitors; different mechanisms. EPO/erythropoietin (sport/anaemia): Spirulina supports EPO-responsiveness (iron provision for erythropoiesis); does not independently stimulate EPO (not doping concern at supplement doses). PHD inhibitors (roxadustat/daprodustat; HIF-PHD inhibitors; renal anaemia): Spirulina iron/2-OG support could partially counter PHD inhibition; spirulina not appropriate to combine with PHD inhibitor therapy. Anti-VEGF (bevacizumab): Spirulina VEGF reduction (inflammatory HIF arm) complementary; does not antagonise direct anti-VEGF antibody. High-altitude acclimatisation: Spirulina iron supports altitude erythropoiesis; antioxidants may slightly blunt hormetic HIF-1α at altitude; net benefit in iron-marginal athletes. Summary: HIF-1α −20–30% (normoxic-inflammatory), VEGF −15–25%, Hb +0.3–0.7 g/dL; dosing 5–10g daily. NK concern: low.